PT - JOURNAL ARTICLE AU - Donald A. Mahler AU - Marc Decramer AU - Anthony D'Urzo AU - Heinrich Worth AU - Tracy White AU - Vijay K.T. Alagappan AU - Hungta Chen AU - Nicola Gallagher AU - Károly Kulich AU - Donald Banerji TI - Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study AID - 10.1183/09031936.00124013 DP - 2014 Jun 01 TA - European Respiratory Journal PG - 1599--1609 VI - 43 IP - 6 4099 - http://erj.ersjournals.com/content/43/6/1599.short 4100 - http://erj.ersjournals.com/content/43/6/1599.full SO - Eur Respir J2014 Jun 01; 43 AB - We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease. In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110/50 μg, placebo or tiotropium 18 μg. Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks. Secondary end-points included lung function, rescue medication use and safety. After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149 versus placebo (least squares mean (LSM) treatment difference 1.37, p<0.001) and tiotropium (LSM treatment difference 0.49, p=0.021). QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0–4 h post-dose versus placebo and tiotropium at day 1 and week 6 (all p<0.001). Rescue medication use was significantly lower with QVA149 versus placebo (p<0.001) and tiotropium (p=0.002). All treatments were well tolerated. Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function versus placebo and tiotropium. These benefits were associated with improvements in other symptoms and reduced use of rescue medication. Two different bronchodilators in a single inhaler were effective in relieving patient-reported dyspnoea in COPD http://ow.ly/qjIpe